Diclofenac, topical — Competitive Intelligence Brief

Diclofenac, topical (Diclofenac, topical) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nonsteroidal anti-inflammatory drug (NSAID). Area: Pain Management / Rheumatology.

marketed Nonsteroidal anti-inflammatory drug (NSAID) Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2) Pain Management / Rheumatology Small molecule

Target snapshot

Diclofenac, topical (Diclofenac, topical) — Nuvo Research Inc.. Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain at the site of application.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Diclofenac, topical TARGET	Diclofenac, topical	Nuvo Research Inc.	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2)
Ketorolac Nasal Spray	Ketorolac Nasal Spray	Hersh, Elliot V., DMD, MS, PhD	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase (COX-1 and COX-2)
Pranoprofen Eyedrops	Pranoprofen Eyedrops	Università degli Studi di Brescia	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase (COX-1, COX-2)
Plain aspirin	Plain aspirin	Royal College of Surgeons, Ireland	marketed	Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent	Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2)
Metamizole and Ibuprofen	Metamizole and Ibuprofen	University Hospital, Basel, Switzerland	marketed	Nonsteroidal anti-inflammatory drug (NSAID) combination	Cyclooxygenase (COX-1 and COX-2)
NSAI treatment	NSAI treatment	London School of Hygiene and Tropical Medicine	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase (COX-1 and/or COX-2)
Topical diclofenac sodium gel	Topical diclofenac sodium gel	Guang'anmen Hospital of China Academy of Chinese Medical Sciences	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1 and COX-2 enzymes

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nonsteroidal anti-inflammatory drug (NSAID) class)

1. Università degli Studi di Brescia · 4 drugs in this class
2. Bausch & Lomb Incorporated · 4 drugs in this class
3. Bayer · 3 drugs in this class
4. Pfizer · 3 drugs in this class
5. Azienda USL Reggio Emilia - IRCCS · 3 drugs in this class
6. Organon and Co · 3 drugs in this class
7. Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division · 2 drugs in this class
8. Bezmialem Vakif University · 2 drugs in this class
9. Guang'anmen Hospital of China Academy of Chinese Medical Sciences · 2 drugs in this class
10. Center For Excellence In Eye Care · 2 drugs in this class